^
    Back
    Association details:
    Biomarker:BCL2 expression
    Cancer:Hodgkin Lymphoma
    Regimen: (bleomycin + dacarbazine + doxorubicin hydrochloride + vinblastine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    EHA 2018
    Title:

    ACTIVATED CASPASE-3 EXPRESSION BY HODGKIN AND REED-STERNBERG CELLS (HRS) IS A POWERFUL PROGNOSTIC FACTOR IN CLASSICAL HODGKIN LYMPHOMA (CHL) TREATED WITH ABVD OR EQUIVALENT REGIMENS

    Published date:
    05/17/2018
    Excerpt:
    Eligible patients had biopsy-proven cHL treated with ABVD or equivalent regimens...BCL2 expression also correlated with inferior FFP (p=0.004).